← All candidates
Two insider buys in the last year — $323.7K in all.
30 filings on record.
IRDOpus Genetics, Inc.
NasdaqCM · Healthcare · $448.43M
$5.41
-7.04% today
Two insider buys in the last year — $323.7K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 2 buys● 6 sells◆ 8 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 3×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what IRD ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$448.43M
Float
64.1M
77% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
45.5
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Gallagher Cam
Bought $163.4K on Dec 29 — 83,000 sh @ $1.97, held indirect, 100% of their stake.
First Form 4 on file
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
25 more transactions on Pro →Context
Wall St
$10.56 avg target
+95.1% vs today · 18 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
1 of 4 quarters beat
Q1 '26−$0.75 act−$0.61
Q4 '25−$0.21 act−$0.11
Q3 '25−$0.25 act−$0.12
Q2 '25−$0.12 act+$0.14
Coverage
RBC Capital Bullish On Opus Genetics (IRD) Amid Limited Competition And De-Risked SetupInsider Monkey · 07-05Guggenheim Initiates Coverage Of Opus Genetics (IRD) With “Buy” Rating And $16 Price TargetInsider Monkey · 06-10Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data CatalystMarketBeat · 05-26Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates
The file stays open
30 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice